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Efforts to design an effective antibody-based vaccine against HIV-1
would beneﬁt from understanding how germ-line B-cell receptors
(BCRs) recognize the HIV-1 gp120/gp41 envelope spike. Potent
VRC01-like (PVL) HIV-1 antibodies derived from the VH1-2*02 germ-
line allele target the conserved CD4 binding site on gp120. A bottle-
neck for design of immunogens capable of eliciting PVL antibodies is
that VH1-2*02 germ-line BCR interactions with gp120 are uncharac-
terized. Here, we report the structure of a VH1-2*02 germ-line anti-
body alone and a germ-line heavy-chain/mature light-chain chimeric
antibody complexed with HIV-1 gp120. VH1-2*02 residues make ex-
tensive contacts with the gp120 outer domain, including all PVL sig-
nature and CD4 mimicry interactions, but not critical CDRH3 contacts
with the gp120 inner domain and bridging sheet that are responsible
for the improved potency of NIH45-46 over closely related clonal var-
iants, such as VRC01. Our results provide insight into initial recogni-
tion of HIV-1 by VH1-2*02 germ-line BCRs and may facilitate the
design of immunogens tailored to engage and stimulate broad and
potent CD4 binding site antibodies.
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Over 30 y after the emergence of HIV-1, there is no effectivevaccine, and AIDS remains an important threat to global
public health. After infection by HIV-1, the host immune response
is unable to clear the virus because of a variety of factors, including
rapid viral mutation and establishment of latent reservoirs (1). The
only target of neutralizing Abs is the trimeric envelope (Env) spike
complex (2, 3), but HIV-1 can usually evade antispike Abs because
of rapid mutation of its two spike glycoproteins, gp120 and gp41,
and structural features that allow the spike to hide conserved
epitopes. These structural features include a dense layer of car-
bohydrates that mask its surface, conformational ﬂexibility, and
variable loops emanating from gp120 (4, 5). The oligomeric
structure of the spike further conceals conserved regions at subunit
interfaces or in narrow inaccessible pockets (6–8), and the low
density of spikes on the surface of HIV virions impedes bivalent
binding of Abs (9, 10).
Nevertheless, broadly neutralizing Abs (bNAbs) that can neu-
tralize many HIV-1 strains have been identiﬁed in HIV-1–infec-
ted individuals (11, 12). The potential of the ﬁrst such bNAbs,
typiﬁed by 4E10, 2F5, 2G12, and b12, to prevent HIV infection in
macaques (13–16) and delay viral rebound after highly active
antiretroviral therapy (HAART) secession (17) made them par-
ticularly interesting for vaccine design efforts. Recently, highly
potent bNAbs that have unprecedented potency and breadth for
HIV neutralization were isolated from infected individuals (18–
22). Of particular interest are Abs that target the relatively con-
served binding site on gp120 for CD4, the host receptor for HIV-1
(20, 23–25). Crystal structures of several such Abs bound to gp120
(23–25) revealed molecular details of their neutralization mecha-
nisms and facilitated structure-based rational design to improve
their potency and breadth (24). The therapeutic potential of the
new bNAbs is signiﬁcant; for the ﬁrst time, a mixture of passively
delivered bNAbs was shown to suppress and control HIV-1 vire-
mia in humanized mice (26). Thus, eliciting similar bNAbs by
vaccination would be highly desirable.
Of importance for potential vaccine efforts, potent anti-CD4
binding site (CD4bs) Abs protect against HIV-1 infection in animal
models (27, 28). These Abs were isolated from several different
individuals (19, 20), and many of the more potent Abs are derived
from a common germ-line gene segment allele (VH1-2*02) that is
present in up to 95% of the population (19, 20, 23, 29). These
observations suggest that similar CD4bs bNAbs could be elicited in
other individuals. Available structural information, together with
sequence and neutralization data for CD4bs Abs, allowed us to
rationalize the structural basis of the VH1-2*02 germ-line gene
usage, determine which Abs bind gp120 similarly, and identify
the critical sequence features that permit this binding (29). Based
on inspection of Ab variable domain sequences, we found that
VH1-2*02-derived Abs completely conserve Arg71HC, Trp50HC,
Asn58HC, and Trp100BHC (Trp102HC in NIH45-46 numbering)
within the heavy chain. Within the light chain, Glu96LC and a
complementarity-determining region (CDR) L3 length of exactly 5
amino acids are conserved (29). We proposed a nomenclature to
describe the class of Abs including this set of sequence character-
istics: potent VRC01-like (PVL)Abs, reﬂecting the ﬁrst antibody of
this class to be isolated (19). The required signature residues ra-
tionalize the VH1-2*02 germ-line gene origins of PVL Abs (29).
The initial recognition of HIV-1 by the VH1-2*02 B-cell re-
ceptor (BCR) might be a limiting factor for eliciting protective
PVL Abs (30). The details of recognition of antigen by a germ-line
BCR are not fully understood, but presumably, the interaction is
sufﬁciently strong in certain individuals to yield a clonal expansion
of the B cells carrying a VH1-2*02 BCR. The binding interaction is
then strengthened by somatic hypermutation and clonal selection,
ultimately leading to a PVL Ab. Although the rare emergence of
B cells that produce bNAbs remains poorly understood, with struc-
tural information about the VH1-2*02 interaction, it may be pos-
sible to design immunogens capable of initiating clonal expansion
from this germ-line allele, leading to an increased chance of mat-
uration to a PVL bNAb. Here, we investigate the structural basis
of recognition by a putative VH1-2*02 germ-line Ab of HIV-1
gp120 through analyses of the crystal structures of a chimeric VH1-
2*02 germ-line/mature light-chain Ab bound to gp120 and the un-
bound germ-line Ab. Structural comparisons show that the heavy-
chain PVL signature residuesmake the same contacts to the gp120
outer domain in the germ-line and mature NIH45-46 Abs but that
critical contacts with the gp120 inner domain and bridging sheet
are not formed by the germ-line Ab. These results suggest
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a pathway by which PVL Abs mature to achieve broad and potent
neutralization and provide insights to guide vaccine immunogen
design to eliciting PVL Abs.
Results
Construction of Germ-Line Precursor Antibody. We constructed a
putative VH1-2*02 germ-line sequence based on the sequence of
NIH45-46, a more potent clonal variant of VRC01 that was iso-
lated from the same donor (20). We used the ImMunoGeneTics
database (IMGT) (31) to predict the V-D-J and V-J assignments
for the heavy and light chains (IGHV1-2*02–IGHD2-15*01–
IGHJ2*01/IGKV3-11*01–IGKJ2*01). Mature NIH45-46 (NIH45-
46mature) differs from the resulting putative germ-line Ab (NIH45-
46GL) by a large number of somatic mutations in both the heavy
and light chains (44 of 126 and 27 of 103 residue differences, re-
spectively) (Fig. 1A and Fig. S1).
Because of the difﬁculty of accurately predicting the residues
present in the CDR3 loops of a germ-line progenitor, the mature
CDRH3 and CDRL3 sequences were used in our NIH45-46GL
construct. We also included a four-residue “insertion” (residues
Ala99a-Arg99b-Asp99c-Tyr99d) within the CDRH3 of NIH45-
46 in our putative germ-line precursor sequence. These residues,
which account for the increased potency of NIH45-46 compared
with VRC01 (20, 24), could have resulted from N-region addition
during V-D-J recombination of the germ-line gene segments or
through somatic hypermutation. However, sequencing of VRC01-
like Ab genes from the VRC01/NIH45-46 donor suggested the
existence of these residues early in the development of VH1-
2*02-derived bNAbs (32), implying that the NIH45-46 germ-line
BCR contained the “insertion”.
Crystal Structure of Germ-Line NIH45-46 Fab. To examine the
structural determinants of differences between mature PVL Abs
and their VH1-2*02-derived germ-line precursor, we crystallized
and solved the structure of the NIH45-46GL Fab (Fig. 1B and
Table S1). Compared with NIH45-46mature, NIH45-46GL Fab
showed no major displacements of CDRs or framework regions
(RMSD = 1.40 Å for 212 Cα atoms), with the exception of
CDRH3 (third CDR in the heavy chain) (Fig. 1B). A non-
canonical disulﬁde bond joining CDRH1 and CDRH3 in NIH45-
46mature is not present in NIH45-46GL, which lacks Cys32CDRH1
(Fig. S2C). The conformation of CDRH3 of NIH45-46GL is,
therefore, not constrained by a disulﬁde bond, and this increased
ﬂexibility could facilitate the different packing in the NIH45-46GL
Fab crystals (Fig. S2D). Although afﬁnity maturation did not
produce signiﬁcant structural rearrangements of the combining site
with the exception of CDRH3, the large number of somatic
mutations introduced in CDRs and framework regions of both
heavy and light chain resulted in a signiﬁcantly resurfaced com-
bining site in NIH45-46mature compared with the putative germ-line
precursor (Fig. S2E).
Crystal Structure of Chimeric Germ-Line NIH45-46 Fab in Complex
with gp120. Consistent with previous reports of no detectable
HIV-1 antigen binding by bNAb germ-line precursors (20, 25, 29,
33, 34), NIH45-46GL failed to interact with clade A/E 93TH057
gp120 coupled to a sensor chip in surface plasmon resonance
(SPR) experiments (Fig. S3A) and did not neutralize HIV-1
pseudoviruses in an in vitro neutralization assay (Fig. S3B).
However, a chimeric Ab consisting of the germ-line heavy chain
and the mature NIH45-46 light chain (NIH45-46chim) showed an
intermediate level of binding in SPR experiments and weak
neutralization in three of seven HIV-1 strains that were potently
neutralized by NIH45-46mature (Fig. S3).
Detectable binding between the NIH45-46chim construct and
gp120 allowed us to investigate the VH1-2*02 interaction with
Env, and because the majority of gp120 contacts in PVL Abs is due
to interactions with the heavy chain (23–25, 29), the structural in-
formation gathered using the chimera would be useful in un-
derstanding the native VH1-2*02 germ-line Ab interaction. To
visualize the interaction between a germ-line variable heavy (VH)
domain and gp120, we solved the crystal structure of NIH45-46chim
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Fig. 1. Crystal structures of NIH45-46GL Fab and NIH45-46chim/gp120 complex. (A) Alignments of VH and VL sequences of mature NIH45-46 (NIH45-46mature)
and its putative germ-line progenitor (NIH45-46GL). Residues forming the CDR loops are colored blue (CDR1), green (CDR2), and red (CDR3). Two cysteines
forming a disulﬁde bond between CDRH1 and CDRH3 of NIH45-46mature are marked with an asterisk. The CDR3 regions were taken from NIH45-46mature,
because the germ-line conﬁguration is unknown. (B) Superimposition of NIH45-46GL Fab and NIH45-46mature Fab shown as wire representations with NIH45-
46GL Fab HC/LC in magenta/light pink and NIH45-46mature Fab HC/LC in teal/light teal. The disulﬁde bond formed between C32CDRH1 and C98CDRH3 of NIH45-
46mature but not NIH45-46GL is marked with an asterisk. The CDR loops are colored as in A. (C) Ribbon diagram of crystal structure of NIH45-46chim (purple,
germ-line heavy chain; pink, mature light chain) bound to gp120 core (yellow, inner domain; gray, outer domain). The disordered tip of CDRH3 is shown as
a dashed line. The gp120 core construct is derived from 93TH053 gp120, but it lacks three variable loops (V1-V2 and V3) and contains N- and C-terminal
truncations (25). Subdomains of gp120 are colored as follows: orange, bridging sheet; blue, CD4 binding loop; green, loop D; cyan, loop V5.
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Fab bound to 93TH057 gp120 at 3.25 Å resolution (Fig. 1C and
Table S1). As used for previous crystallographic studies (20, 23–
25), the gp120 was a core construct with truncations (N/C termini
and loops V1-V2 and V3). We superimposed the gp120 cores from
NIH45-46chim/gp120 and NIH45-46mature/gp120 complex structures
(Fig. 2A) to compare the recognition of gp120 by the germ-line and
NIH45-46mature Ab heavy chains (24). The variable domains of
NIH45-46chim and NIH45-46mature aligned closely (RMSD =
0.68 Å; 209 Cαs), showing that the angle at which the Ab approaches
gp120 is not altered by afﬁnity maturation. Also, similar to the
NIH45-46mature/93TH057 complex structure (Protein Data Bank
ID code 3U7Y), NIH45-46chim contacts the outer domain of
gp120, including the CD4 binding loop, loop D, and loop V5.
To quantify differences in the binding interfaces between the
NIH45-46chim and NIH45-46mature complexes with gp120, we
calculated their buried surface areas (BSAs) upon binding
(Fig. 2 B and C and Fig. S4). Like NIH45-46mature, NIH45-46chim
primarily contacts gp120 through its heavy chain (84% and 85% of
the BSA for NIH45-46chim and NIH45-46mature, respectively), in-
cluding gp120 contacts with all CDRH loops and residues in
heavy-chain framework regions (FWRs) 2 and 3 (Fig. S4). The
BSA on gp120 in the NIH45-46chim complex is ∼68% of the sur-
face area buried in the interface with NIH45-46mature (Fig. 2 B and
C). However, almost all of the additional contacts made by
NIH45-46mature involve the inner domain and bridging sheet of
gp120, whereas an equal surface area of the outer domain is
contacted in both complexes (Fig. 2 B and C). NIH45-46mature
makes these additional interactions using CDRH3 and somatically
mutated residues in CDRH1 and FWR3 (Fig. S4). Therefore,
although the location of the contact surfaces is similar in both
complexes (except for the gp120 inner domain), afﬁnity matura-
tion increased the surface area buried on both the antibody and
gp120 by 66% and 47%, respectively, which improved the strength
and speciﬁcity of binding.
NIH45-46 Germ-Line Heavy Chain Makes PVL Signature and CD4
Binding Loop Contacts. The VH1-2*02 germ-line allele and PVL
Abs derived from it share a set of distinct residues [Trp50HC,
Asn58HC, Arg71HC, and Trp102HC (Trp100BHC in VRC01 num-
bering)] predicted to engage in conserved interactions with the
CD4bs on gp120 (29); thus, we were able to examine the con-
formations and potential interactions of these residues in the
NIH45-46chim/gp120 complex structure. We found that the germ-
line VH of NIH45-46chim is positioned to make all of the conserved
PVL signature VH/gp120 contacts (Fig. 3 A and B). In particular,
Trp50HC (FWR2) and Asn58HC (FWR3) are within hydrogen
bonding distance of Asn280gp120 and Arg456gp120, respectively, and
Trp102HC (Trp100BHC in VRC01 numbering; CDRH3) (29) hy-
drogen bonds with Asn279gp120 (Fig. 3A). Lastly, the salt bridge
between Arg71HC (FWR3) and Asp368gp120, which mimics the
Arg59CD4–Asp368gp120 interaction (6), is also made by the germ-
line VH of NIH45-46chim (Fig. 3B). Preservation of the PVL sig-
nature residue interactions in the germ-line VH domain conﬁrms
the prediction that these residues are critical for establishing
binding to gp120 (29).
The two PVL signature residues of the variable light chain (VL;
Trp67 and Glu96) were acquired by somatic hypermutation and
thus, could not contribute to the binding of the germ-line Ab to
gp120. To investigate limiting factors that restrict germ-line VL/
gp120 interaction, we superimposed the structure of NIH45-46GL
onto the NIH45-46chim/gp120 complex (Fig. S5A). Gln96LC GL
(CDRL3) is positioned within hydrogen bonding distance of
Gly459gp120 and Asn280gp120, similar to Glu96LC NIH45-46 (Fig.
3C). The conserved Trp67LC that interacts with the Asn276gp120-
attached N-glycan (29) in mature PVL Abs is a serine in the
germ-line Ab. Combined with the increased length of CDRL1
caused by a two-residue insertion in NIH45-46GL (Fig. 1A and
Fig. S1), VL GL may not be compatible with interacting with the
Asn276gp120-attached N-glycan (Fig. S5B).
PVL Abs mimic CD4 by engaging the CD4 binding loop on
gp120 with backbone atoms in the C″ strand of VH (23–25).
NIH45-46mature makes direct and water-mediated hydrogen bonds
using main-chain atoms of Gly54HC and Val57HC to contact
Ser365gp120, Gly366gp120, and Asp368gp120 (Fig. 3D), mimicking
the contacts between Leu44CD4 and Lys46CD4 with the CD4
binding loop (24). In addition to a direct main-chain hydrogen
bond between Ser54HC and Asp368gp120, the germ-line VH of
NIH45-46chim makes two other hydrogen bonds: between Gly55HC
andAsp367gp120 and between the side chains of Thr57HC (Val57 in
NIH45-46mature) and Ser365gp120 (Fig. 3E). Although ordered
water molecules were not resolved in the 3.25 Å NIH45-46chim/
gp120 complex structure, Thr57HC NIH45-46 chim could participate in
a hydrogen bonding network analogous to and possibly more ex-
tensive than the network established by Val57HC NIH45-46 and
Gly366gp120/Asp368gp120 in the NIH45-46mature/gp120 structure
that included ordered water molecules (Fig. 3E). In summary, our
structural analyses showed that NIH45-46GL relies on C″ strand
contacts with the CD4 binding loop of gp120 as well as the PVL
signature contacts with the CD4 binding loop, the V5 loop, and
loop D to bind to gp120.
Loss of gp120 Inner Domain Contacts by the Germ-Line NIH45-46
Heavy Chain. Although many contacts made by VH NIH45-46 mature
with gp120 are also observed in the NIH45-46chim/gp120 structure,
NIH45-46chim does not appreciably interact with the inner do-
main of gp120. By contrast, NIH45-46mature uses a four-residue
“insertion” in CDRH3 (Ala99a-Arg99b-Asp99c-Tyr99d), which is
critical for its increased neutralization potency compared with
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Fig. 2. Comparison of the binding interfaces of
NIH45-46chim/gp120 and NIH45-46mature/gp120. (A) Su-
perimposition of complex crystal structures of NIH45-
46chim/gp120 (purple, Ab heavy chain; light pink, Ab
light chain) and NIH45-46mature/gp120 (teal, Ab heavy
chain; light teal, Ab light chain). The crystal structures
were superimposed on their gp120s (domain coloring
as in Fig. 1C). The protein backbones are shown as wire
diagrams, and the disordered tip of CDRH3 is shown as
a dashed line. (B) Comparison of binding interfaces in
NIH45-46chim/gp120 and NIH45-46mature/gp120 com-
plexes. Surface area buried by Fabs on gp120 because
of complex formation was calculated using a 1.4-Å
probe. Residues at each contact interface are high-
lighted on the ribbon diagrams of gp120 complexed
with NIH45-46chim Fab (Left) or NIH45-46mature (Right)
as surfaces enclosing the contact residues. Coloring as
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VRC01, to contact the gp120 inner domain (24). The loss of
gp120 inner domain contacts by NIH45-46chim results from dis-
ordered residues forming the tip of CDRH3NIH45-46 chim (heavy-
chain residues 99–99c), including three of four “insertion” resi-
dues (Fig. 1C). In addition, the base of CDRH3NIH45-46chim is
turned away from gp120 by ∼5.5 Å (Fig. 4A), possibly because of
the lack of the CDRH1–CDRH3 disulﬁde bond in the germ-line
VH domain and the bulky side chain of Tyr33HC in NIH45-
46chim occupying space created by the smaller Pro33HC residue
in NIH45-46mature (Fig. S6A). The Cys32CDRH1–Cys98CDRH3
disulﬁde bond helps ﬁx the conformation of CDRH3NIH45-46, po-
tentially facilitating extensive interactions with the inner domain
of gp120. The “insertion” in CDRH3NIH45-46 contacts inner domain
residues, including Lys97gp120, Asn99gp120, Glu102gp120, Asn474gp120,
Lys476gp120, and Arg480gp120, whereas NIH45-46chim makes none of
these inner domain contacts because of its displaced CDRH3
(Fig. 4B and Fig. S6B). In the NIH45-46chim/gp120 structure, in-
ner domain residues Asn474gp120, Lys476gp120, and Arg480gp120
coordinate a sulfate ion not found in the NIH45-46mature/gp120
complex, verifying that CDRH3NIH45-46chim does not interact with
gp120 (Fig. 4B and Fig. S6B). The fourth CDRH3 “insertion”
residue, Tyr99dNIH45-46 chim, is ordered, but because of the dis-
placement of CDRH3, it cannot interact with gp120 loop D res-
idues Ala281gp120 and Lys282gp120 as in the gp120 complex with
NIH45-46mature (Fig. S6C). The inner domain and loop D con-
tacts made by NIH45-46mature contribute most of the additional
BSA on gp120 and therefore, may be partially responsible for the
improved binding afﬁnity and neutralization potency of NIH45-
46mature over NIH45-46GL.
Discussion
The recently isolated group of PVL Abs directed against the
CD4bs on HIV-1 gp120 comprises the most potent and broadly
neutralizing set of anti–HIV-1 Abs characterized to date, making
it a promising target for HIV-1 vaccine development (20, 23–25,
29). Despite being derived from different HIV-1-infected donors
in response to different eliciting viruses (20), PVL Abs share
a set of conserved heavy-chain residues that are crucial for gp120
recognition and present in the VH1-2*02 germ line from which
they are derived (29). Detailed structural information about how
germ-line precursor Abs might engage gp120 would aid immu-
nogen design by identifying speciﬁc features that foster the clonal
selection of these Abs (30). However, structures of a PVL germ-
line precursor bound to gp120 or any anti–HIV-1 germ-line Ab
bound to an HIV-1 antigen have been unavailable. Indeed, al-
though such structures would facilitate design of immunogens
capable of eliciting neutralizing Abs, structural characterizations
of antigen recognition by germ-line Abs against other viruses are
rare: other examples include germ-line Ab recognition of in-
ﬂuenza (35) and human cytomegalovirus (36) antigens. Here, we
report a crystal structure of a gp120 complexed with a Fab
containing a putative germ-line heavy chain: in this case, a chi-
meric Fab consisting of the germ-line heavy chain and mature
light chain of the PVL Ab NIH45-46 (NIH45-46chim). Compar-
isons with the structure of mature NIH45-46 (NIH45-46mature)
bound to the same gp120 (24) are relevant to understanding how
clonal selection progresses from initial recognition of a germ-line
Ab to rounds of somatic hypermutation that improve binding,
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interacting residues are shown as sticks (red, oxygen; blue, nitrogen). (A)
Trp50HC-Asn280gp120, Asn58HC-Arg456gp120, Trp102HC-Asn279gp120 (in VRC01
numbering, Trp100BHC-Asn279gp120) (29), Glu96LC-Asn280gp120, and Glu96LC-
Gly459gp120. (B) Arg71HC-Asp368gp120. Orange and yellow dashed lines show
potential hydrogen bonds in NIH45-46chim/gp120 and NIH45-46mature/gp120
complexes, respectively. (C) Superimposition of NIH45-46GL Fab on the
NIH45-46chim/gp120 complex. The PVL-characteristic Glu96LC–Asn280gp120
and Glu96LC–Gly459gp120 interactions can be established by the germ-line
light chain and are shown as teal dashed lines. (D and E) Contacts between
the gp120 CD4 binding loop (gray) and the heavy chain of (D) NIH45-46mature
(teal) or (E) NIH45-46chim (purple). The protein atoms are shown as sticks
(red, oxygens; blue, nitrogens); ordered water molecules in the NIH45-
46mature/gp120 complex are shown as red spheres, and their corresponding
locations in the NIH45-46chim/gp120 complex (not observed at 3.25 Å reso-
lution) are shown as red circles. Probable hydrogen bonds (distance < 3.5 Å,
A-H–D angle > 90°) are shown as yellow dashed lines. Possible hydrogen
bonds (distance < 4 Å or rely on water molecules not observed) are shown as
teal dashed lines.
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Fig. 4. Displacement of CDRH3 in NIH45-46chim/gp120 structure results in
loss of gp120 inner domain contacts. (A) Superimposition of the NIH45-
46chim/gp120 and NIH45-46mature/gp120 complexes on gp120 shows that the
base of CDRH3NIH45-46chim (Cys98) is displaced away from gp120 by ∼5.5 Å
relative to the NIH45-46mature/gp120 complex. The four residues forming the
tip of CDRH3 are disordered in our NIH45-46chim/gp120 complex structure
and could extend even farther away from gp120 (purple, NIH45-46chim heavy
chain; teal, NIH45-46mature heavy chain; gp120 domain coloring as in Fig. 1C).
(B) Detailed view of gp120 inner domain contacts made by CDRH3NIH45-46 mature
(teal) but not CDRH3NIH45-46 chim (purple). Protein backbones are shown as wire
representations, and amino acid side chains are shown as sticks. The dis-
ordered part of CDRH3NIH45-46 chim is shown as a dashed line. A sulfate ion
coordinated by Asn474gp120, Lys476gp120, and Arg480gp120 in the NIH45-
46chim–bound structure (gp120 residues in gray) but not the NIH45-46mature–
bound structure (gp120 residues in white) is shown as sticks. Sulfur, oxygen,
and nitrogen atoms are colored yellow, red, and blue, respectively.
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which is critical information for design of immunogens to elicit
PVL Abs. Although we cannot be certain that this germ-line
heavy chain is identical to the heavy chain of the initial BCR in
patient 45 from whom NIH45-46 was isolated (20), it is repre-
sentative of the various germ-line regions in the general pop-
ulation that will need to be targeted by a vaccine.
The orientation by which the 93TH057 gp120 is recognized by
NIH45-46chim and NIH45-46mature is similar. Thus, the general
mechanism bywhich theVHdomain of a PVLAbmimics CD4 (25)
is present in the initial BCR/gp120 recognition event. Importantly,
we found that extensive contacts are established by VH1-2*02
residues (including most of the PVL signature residues) of the
germ-line Ab with the gp120 outer domain. Indeed, the size of the
germ-line VH domain interface with the gp120 outer domain was
similar to the interface formed with the mature VH domain.
However, additional contacts with the gp120 inner domain and
bridging sheet caused nearly a 50% increase in the BSA on gp120
by NIH45-46mature compared with NIH45-46chim. This additional
contact area likely contributes to the greatly increased binding
afﬁnity and neutralization potency of NIH45-46mature. Thus, spe-
ciﬁc outer domain contacts, including PVL signature residue
contacts and main-chain contacts between CDRH2 and the CD4
binding loop, were present in the VH domain germ-line precursor–
gp120 complex, whereas contacts with the gp120 inner domain
and bridging sheet required changes induced by somatic hyper-
mutation and therefore, were largely absent in the NIH45-46chim/
gp120 complex structure.Of direct relevance to immunogendesign
efforts, this result suggests that modiﬁed outer domain-only gp120
constructs might be capable of triggering a germ-line BCR for
a VH1-2*02-derived Ab but that afﬁnity maturation to a PVL Ab
would likely require subsequent boosting with Env constructs, in-
cluding native residues in the gp120 inner domain and bridging
sheet. Thus, modiﬁed outer domain immunogens having an in-
creased afﬁnity for the VH1-2*02-derived germ line could only
serve to trigger the initial immune response; more complete gp120
immunogens containing the inner domain and the bridging sheet
would be required to drive afﬁnity maturation.
The ﬁnding that the chimeric Ab relied almost exclusively on
VH1-2*02 germ-line contacts with the gp120 outer domain is also
important for understanding the structural correlates of broad
and potent neutralization by PVL Abs. Previous structural studies
deﬁned the initial CD4 attachment site on the gp120 outer do-
main as a desirable target, concluding that increased contact with
the CD4bs on the gp120 inner domain and bridging sheet (de-
ﬁned as outside the initial CD4 attachment site) correlated with
decreased breadth and potency (23, 25). Therefore, CD4/bNAb
contact regions on the gp120 inner domain/bridging sheet were
deliberately modiﬁed to create a resurfaced gp120 core, which
was used as bait for isolating bNAbs (19, 23) and as a candidate
HIV immunogen (37). However, structural comparison between
two closely related bNAbs, NIH45-46 and VRC01 (86% identity
in VH; 96% in VL), subsequently revealed that increased contact
area with regions outside of the gp120 outer domain does not
correlate with decreased neutralization potency and breadth,
because NIH45-46 showed more extensive contacts (relative to
VRC01) with the inner domain and bridging sheet of gp120 (24)
but is more potent (20). The present study, comparing germ-line
and mature antibody recognition of gp120, more dramatically
illustrates this principle, because NIH45-46chim shows much
weaker binding and neutralization activity than NIH45-46mature
but interacts almost exclusively with the gp120 outer domain.
The germ-line version of the VH1-2*02 VH domain used for
our complex structure included a four-residue “insertion” within
the CDRH3 of NIH45-46 responsible for the increased potency
of NIH45-46 compared with VRC01 (20, 24). Although the in-
sertion made extensive contacts with the gp120 inner domain in
the NIH45-46mature/gp120 structure, this region of CDRH3 was
partially disordered in the NIH45-46chim/gp120 complex. The lack
of contacts with CDRH3NIH45-46chim may be, in part, because of
the missing CDRH1–CDRH3 disulﬁde bond and/or a bulkier
residue (Tyr33NIH45-46GL compared with Pro33NIH45-46 mature)
displacing CDRH3 away from gp120. The absence of this disul-
ﬁde bond leaves an unpaired cysteine residue at the base of
CDRH3, which is energetically unfavored and may lead to ag-
gregation. It is possible that the CDRH3 sequence in the germ-
line Ab from the NIH45-46/VRC01 donor that was the precursor
to NIH45-46 contained different residues that would have been
replaced or deleted during maturation and are not reﬂected in
the CDRH3 sequence used in our construct. It is also possible
that the higher ﬂexibility of the germ-lineAb lacking the disulﬁde
linkage would broaden the number of similar targets that can be
recognized while having a minimal effect on binding. The
CDRH1–CDRH3 disulﬁde bond may play an important role in
maturation by restricting the allowable CDRH3 conformations,
perhaps providing more rigidity (decrease in entropy) that per-
mits a collection of relatively weak interactions to form a func-
tional binding surface. Interestingly, the heavy chains of some
shark Abs [type II immunoglobulin new antigen receptors
(IgNAR)] contain an analogous CDRH1–CDRH3 disulﬁde bond
that is thought to stabilize select conformations of their extended
CDRH3 loop (38). Furthermore, increasing the rigidity of CDRs
during afﬁnity maturation was also described for broadly neutral-
izing antiinﬂuenza antibodies (39). Even if the CDRH1–CDRH3
disulﬁde bond is not essential for the neutralization potency of
NIH45-46mature, immunogens could be designed to encourage its
formation by supporting the introduction of a CDRH1 cysteine
(Tyr32Cys; i.e., an immunogen that would not rely on contacts
with Tyr32HC) or favor the CDRH3 conformation resulting from
the disulﬁde bond.
Key questions to consider for efforts to design immunogens
capable of eliciting PVL Abs include why all HIV-1–infected
individuals do not develop these Abs and why previous Env-based
vaccines failed to elicit protective PVL Abs (reviewed in ref. 30).
The prevalence of a suitable VH1-2*02 allele in the general
population is high (29) and cannot account for the rarity of PVL
Abs. It was shown that B cells expressing BCRs corresponding to
the germ-line precursor of the cross-reactive 2F5 antibody were
eliminated through immunological tolerance (40), but elimina-
tion of PVL precursors seems unlikely, because most PVL Abs do
not show obvious cross-reactivity (20). However, PVL Abs un-
dergo much more extensive somatic hypermutation than typical
human IgGs (19, 20, 23, 41), with 96 nucleotide mutations in the
VH of NIH45-46 (20) compared with an average of 18 mutations
in human IgG memory B cells (42). The high level of somatic
hypermutation required for neutralization breadth and potency
(19, 20) is likely caused by the evolution of gp120 over the course
of several years. The apparent requirement for extensive Ab
hypermutation complicates immunogen design, because succes-
sive administration of different immunogens may be necessary to
drive proper afﬁnity maturation on the path from a VH1-2*02
germ-line predecessor to a highly potent and broadly neutralizing
HIV-1 antibody. Our results illustrate how a BCR might recog-
nize gp120 at the starting point of afﬁnity maturation.
Materials and Methods
Construction of the Germ-Line Version of NIH45-46. NIH45-46GL (20) was con-
structed by reverting all somatic mutations in the V(D)J regions of both
heavy and light chains. The respective germ-line genes were identiﬁed by
BLAST of the antibody sequences in the IMGT database (43). CDR3s were left
in the original mutated forms, because it is impossible to reliably determine
their germ-line conﬁgurations.
Protein Expression and Puriﬁcation. Protein expression and puriﬁcation are
described in detail in SI Materials and Methods. NIH45-46, NIH45-46chim
(germ-line heavy chain/mature light chain), and NIH45-46GL IgGs were
expressed, puriﬁed, and cleaved with papain to generate Fabs as previously
described (24). A 93TH057 gp120 core was produced as described previously
(24). For crystallization, puriﬁed NIH45-46chim Fab and 93TH057 gp120 were
incubated at a 1:1 molar ratio and treated with Endoglycosidase H followed
by size exclusion chromatography puriﬁcation.
Crystallization and Structure Determination. Crystallization, data collection,
structure determinations, and analyses are described in SI Materials and
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Methods. Brieﬂy, crystals of Fab NIH45-46GL (space group P212121, a = 56.0 Å,
b = 70.1 Å, c = 225.1 Å; two molecules per asymmetric unit) were obtained in
30% (wt/vol) PEG 3350, 0.2 M (NH4)2SO4, and 0.1 M Bis·Tris, pH 5.5, at 20 °C.
Crystals of NIH45-46chim–93TH057 gp120 (space group P212121, a = 60.7 Å,
b = 66.1 Å, c = 206.7 Å; one molecule per asymmetric unit) were obtained in
5% (vol/vol) isopropanol, 16% (wt/vol) PEG 10,000, 0.1 M Bis·Tris, pH 6.5, and
80 mM ammonium sulfate at 20 °C. The Fab NIH45-46GL and NIH45-46chim–
93TH057 gp120 complex structures were solved by molecular replacement and
reﬁned to 1.65 (Rwork = 17.4%; Rfree = 20.3%) and 3.25 Å resolution (Rwork =
22.7%; Rfree = 26.7%), respectively. The Fab NIH45-46GL and NIH45-46chim–
93TH057 gp120 complex structures had 98.6%, 1.4%, and 0.0% or 98.5%,
1.4%, and 0.1% of the residues in the favored, allowed, and disallowed
regions, respectively, of the Ramachandran plot.
SPR Measurements. Binding of 93TH057 gp120 core to NIH45-46mature, NIH45-
46chim, and NIH45-46GL IgGs was compared using a Biacore T200 instrument
(GE Healthcare). Puriﬁed gp120 core was immobilized at a coupling density
of 2,000 resonance units on a CM5 sensor chip (Biacore) in 10 mM acetate,
pH 5.0, using primary amine coupling chemistry (Biacore). One ﬂow cell on the
sensor chip was mock-coupled using buffer to serve as a blank. Experiments
were performed at 25 °C in 20 mM Hepes, pH 7.0, 150 mM NaCl, and 0.005%
(vol/vol) P20 surfactant, and the sensor chips were regenerated using 10 mM
glycine, pH 2.5. Abs were injected at a concentration of 62.5 nM (NIH45-
46mature) or 1 μM (NIH45-46chim and NIH45-46GL) at a ﬂow rate of 90 μL/min.
In Vitro Neutralization Assays.We used a pseudovirus neutralization assay (44)
to compare the neutralization potencies of mature, chimeric and germ-line
NIH45-46 IgGs. Brieﬂy, neutralization was assessed by measuring the reduction
in luciferase reporter gene expression in the presence of a potential inhibitor
after a single round of pseudovirus infection in TZM-bl cells. Antibodies were
preincubated with 250 infectious viral units in a three- or fourfold dilution
series for 1 h at 37 °C before adding 10,000 TZM-bl cells per well for a 2-
d incubation. Cells were then lysed, and luciferase expression was measured
using BrightGlo (Promega) and a Victor3 luminometer (PerkinElmer). Non-
linear regression analysis using the program Prism (GraphPad) was used to
calculate the concentrations at which half-maximal inhibition was observed
(IC50 values) as described (45). Samples were screened in duplicate.
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